MktsMarkets

Neurocrine Biosciences, Inc.
NASDAQ: NBIXKey statistics
NBIX News
Stories mentioning NBIX from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 814,500 | 805,500 | 794,900 | 687,500 | 572,600 | 627,700 | 622,100 | 590,200 |
| Cost of Goods Sold | 13,800 | 17,600 | 14,000 | 11,300 | 9,200 | 9,300 | 8,000 | 9,200 |
| Gross Profit | 800,700 | 787,900 | 780,900 | 676,200 | 563,400 | 618,400 | 614,100 | 581,000 |
| Operating Expenses | ||||||||
| Research & Development | ||||||||
| Sales General & Admin | 318,500 | 301,800 | 291,600 | 286,300 | 276,500 | 287,800 | 234,300 | 242,000 |
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | 193,400 | 210,900 | 239,000 | 145,600 | 23,600 | 142,000 | 183,800 | 145,400 |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | 246,800 | 239,400 | 291,800 | 159,500 | 14,700 | 162,600 | 190,300 | 98,600 |
| Tax Provision | 48,900 | 85,700 | 82,300 | 52,000 | 6,800 | 59,500 | 60,500 | 33,600 |
| Net Income (Loss) | 197,900 | 153,700 | 209,500 | 107,500 | 7,900 | 103,100 | 129,800 | 65,000 |
| Earnings Per Share (Basic) | 1.97 | 1.54 | 2.11 | 1.09 | 0.08 | 1.03 | 1.28 | 0.64 |
| Earnings Per Share (Diluted) | 1.91 | 1.50 | 2.04 | 1.06 | 0.08 | 0.99 | 1.24 | 0.63 |
| Weighted Average Shares Outstanding (Basic) | 100,500 | 99,500 | 99,400 | 99,000 | 99,700 | 100,400 | 101,100 | 100,800 |
| Weighted Average Shares Outstanding (Diluted) | 103,400 | 102,500 | 102,500 | 101,000 | 102,500 | 103,700 | 104,300 | 103,900 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About NBIX
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is a stock listed on the Nasdaq Stock Market under the ticker symbol NBIX. It last traded at $164.63 (Nov 6, 2026, 4:00 PM ET), up 3.0% on the day. That gives Neurocrine Biosciences a market capitalisation of $16.7B and a price-to-earnings ratio of 23.7.
Over the past 52 weeks NBIX has traded between $122.14 and $186.12.
Revenue for the quarter ended Mar 31, 2026 was $814.5M; net income $197.9M. Revenue was up 42.2% from $572.6M in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $814.5M | $197.9M | 24.3% |
| Dec 31, 2025 | $805.5M | $153.7M | 19.1% |
| Sep 30, 2025 | $794.9M | $209.5M | 26.4% |
| Jun 30, 2025 | $687.5M | $107.5M | 15.6% |
From Neurocrine Biosciences’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…